Joshua Thurman
Concepts (636)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 46 | 2025 | 314 | 11.940 |
Why?
| | Complement Activation | 68 | 2026 | 399 | 11.340 |
Why?
| | Kidney Diseases | 25 | 2024 | 425 | 8.430 |
Why?
| | Complement Pathway, Alternative | 36 | 2025 | 121 | 6.320 |
Why?
| | Complement Factor H | 19 | 2025 | 79 | 5.750 |
Why?
| | Complement Inactivating Agents | 17 | 2025 | 74 | 4.940 |
Why?
| | Kidney Glomerulus | 18 | 2026 | 125 | 4.900 |
Why?
| | Kidney | 31 | 2023 | 1497 | 3.850 |
Why?
| | Reperfusion Injury | 15 | 2019 | 293 | 3.630 |
Why?
| | Complement Factor B | 25 | 2023 | 106 | 3.580 |
Why?
| | Glomerulonephritis | 9 | 2023 | 44 | 3.510 |
Why?
| | Autoimmune Diseases | 10 | 2025 | 468 | 2.950 |
Why?
| | Immunoglobulin M | 10 | 2025 | 265 | 2.940 |
Why?
| | Complement C3 | 25 | 2023 | 187 | 2.750 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 41 | 2.380 |
Why?
| | Acute Kidney Injury | 13 | 2024 | 875 | 2.290 |
Why?
| | Graft Rejection | 10 | 2025 | 521 | 2.220 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 7 | 2025 | 21 | 2.150 |
Why?
| | Kidney Tubules | 8 | 2024 | 118 | 1.770 |
Why?
| | Receptor, Anaphylatoxin C5a | 7 | 2024 | 35 | 1.670 |
Why?
| | Nephrotic Syndrome | 3 | 2026 | 43 | 1.630 |
Why?
| | Receptors, Complement | 12 | 2026 | 123 | 1.630 |
Why?
| | Lupus Nephritis | 7 | 2021 | 67 | 1.540 |
Why?
| | Endothelial Cells | 8 | 2026 | 874 | 1.540 |
Why?
| | Antibodies | 4 | 2024 | 397 | 1.460 |
Why?
| | Animals | 112 | 2026 | 38030 | 1.450 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 10 | 1.440 |
Why?
| | Kidney Transplantation | 10 | 2025 | 712 | 1.430 |
Why?
| | Annexin A2 | 2 | 2025 | 15 | 1.380 |
Why?
| | Mice | 78 | 2026 | 18329 | 1.380 |
Why?
| | Complement C3d | 10 | 2025 | 62 | 1.360 |
Why?
| | Mice, Knockout | 36 | 2026 | 3124 | 1.350 |
Why?
| | Glomerulonephritis, Membranoproliferative | 6 | 2023 | 25 | 1.320 |
Why?
| | Inflammation | 17 | 2025 | 2878 | 1.300 |
Why?
| | Complement C3b | 4 | 2023 | 29 | 1.280 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 599 | 1.260 |
Why?
| | Epitopes | 8 | 2023 | 473 | 1.240 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 838 | 1.110 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 39 | 1.100 |
Why?
| | Disease Models, Animal | 31 | 2025 | 4560 | 1.100 |
Why?
| | Antibodies, Monoclonal | 17 | 2025 | 1505 | 1.080 |
Why?
| | Epithelial Cells | 10 | 2024 | 1131 | 1.080 |
Why?
| | Mice, Inbred C57BL | 45 | 2025 | 5983 | 1.030 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 15 | 1.030 |
Why?
| | Humans | 108 | 2026 | 145475 | 0.950 |
Why?
| | Contrast Media | 4 | 2018 | 497 | 0.950 |
Why?
| | Complement C5a | 7 | 2024 | 54 | 0.940 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 17 | 0.920 |
Why?
| | Antibodies, Anticardiolipin | 1 | 2025 | 7 | 0.900 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 19 | 0.890 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 73 | 0.880 |
Why?
| | Delayed Graft Function | 1 | 2025 | 46 | 0.880 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.860 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 365 | 0.860 |
Why?
| | Organ Transplantation | 2 | 2019 | 251 | 0.840 |
Why?
| | Biomarkers | 19 | 2025 | 4295 | 0.790 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 956 | 0.770 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 69 | 0.760 |
Why?
| | Nephritis | 2 | 2013 | 22 | 0.760 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 238 | 0.750 |
Why?
| | Immunoglobulin G | 12 | 2025 | 892 | 0.750 |
Why?
| | Complement Membrane Attack Complex | 7 | 2025 | 38 | 0.740 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 25 | 0.730 |
Why?
| | Tissue Donors | 1 | 2025 | 420 | 0.700 |
Why?
| | Podocytes | 4 | 2026 | 80 | 0.680 |
Why?
| | Precision Medicine | 1 | 2025 | 459 | 0.680 |
Why?
| | Autoantibodies | 11 | 2026 | 1509 | 0.670 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 24 | 0.660 |
Why?
| | Cardiolipins | 1 | 2021 | 82 | 0.660 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3904 | 0.650 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 439 | 0.640 |
Why?
| | Cyclosporine | 3 | 2019 | 256 | 0.590 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 7 | 0.580 |
Why?
| | Otitis Media | 5 | 2016 | 182 | 0.570 |
Why?
| | Biomedical Research | 2 | 2025 | 717 | 0.570 |
Why?
| | Vascular System Injuries | 1 | 2019 | 81 | 0.570 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 79 | 0.570 |
Why?
| | Transplantation, Homologous | 4 | 2025 | 418 | 0.560 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.550 |
Why?
| | Doxorubicin | 5 | 2026 | 401 | 0.540 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 103 | 0.540 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 12 | 0.520 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 441 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 992 | 0.500 |
Why?
| | B-Lymphocytes | 7 | 2022 | 870 | 0.500 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 372 | 0.490 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 98 | 0.480 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 668 | 0.480 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 95 | 0.470 |
Why?
| | Renal Insufficiency | 1 | 2018 | 172 | 0.460 |
Why?
| | Peptide Fragments | 1 | 2019 | 693 | 0.450 |
Why?
| | Graft Survival | 5 | 2025 | 518 | 0.440 |
Why?
| | Male | 53 | 2026 | 72843 | 0.440 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 184 | 0.440 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1261 | 0.430 |
Why?
| | Complement C3a | 4 | 2024 | 40 | 0.430 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 27 | 0.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1443 | 0.410 |
Why?
| | Female | 48 | 2026 | 78845 | 0.400 |
Why?
| | Liver Neoplasms | 1 | 2020 | 776 | 0.400 |
Why?
| | Pregnancy Complications | 3 | 2018 | 602 | 0.400 |
Why?
| | Metabolomics | 5 | 2025 | 732 | 0.390 |
Why?
| | Allografts | 3 | 2025 | 152 | 0.390 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 610 | 0.380 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 5 | 0.380 |
Why?
| | Signal Transduction | 11 | 2026 | 5216 | 0.380 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 77 | 0.360 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 273 | 0.360 |
Why?
| | Immunity, Humoral | 1 | 2013 | 118 | 0.360 |
Why?
| | Autoimmunity | 5 | 2022 | 933 | 0.350 |
Why?
| | Molecular Imaging | 1 | 2012 | 57 | 0.350 |
Why?
| | Liver | 2 | 2020 | 1896 | 0.350 |
Why?
| | Complement C1q | 3 | 2014 | 32 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 848 | 0.350 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 125 | 0.340 |
Why?
| | Complement C2 | 2 | 2011 | 8 | 0.330 |
Why?
| | Oxidative Stress | 8 | 2024 | 1356 | 0.330 |
Why?
| | Blotting, Western | 7 | 2016 | 1179 | 0.310 |
Why?
| | CD55 Antigens | 3 | 2020 | 29 | 0.310 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 276 | 0.310 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 25 | 0.310 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 76 | 0.310 |
Why?
| | Cell Membrane | 4 | 2022 | 707 | 0.310 |
Why?
| | Nanoparticles | 2 | 2013 | 517 | 0.310 |
Why?
| | Disease Susceptibility | 2 | 2020 | 344 | 0.300 |
Why?
| | Prognosis | 6 | 2025 | 4316 | 0.300 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 37 | 0.300 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 765 | 0.290 |
Why?
| | Adult | 15 | 2026 | 40777 | 0.290 |
Why?
| | Protozoan Proteins | 3 | 1998 | 90 | 0.290 |
Why?
| | Properdin | 2 | 2020 | 9 | 0.280 |
Why?
| | Cytokines | 5 | 2019 | 2067 | 0.280 |
Why?
| | Antibody Specificity | 2 | 2021 | 178 | 0.280 |
Why?
| | Kidney Function Tests | 2 | 2025 | 156 | 0.280 |
Why?
| | Diarrhea | 1 | 2009 | 193 | 0.280 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.270 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 129 | 0.270 |
Why?
| | Complement C4 | 5 | 2021 | 26 | 0.270 |
Why?
| | Uremia | 2 | 2021 | 15 | 0.270 |
Why?
| | Complement C4b-Binding Protein | 2 | 2026 | 3 | 0.260 |
Why?
| | Disease Progression | 6 | 2025 | 2864 | 0.260 |
Why?
| | Phagocytosis | 4 | 2023 | 296 | 0.260 |
Why?
| | Cell Line | 7 | 2025 | 2823 | 0.260 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 79 | 0.260 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.260 |
Why?
| | Blood Platelets | 2 | 2024 | 379 | 0.260 |
Why?
| | Tandem Mass Spectrometry | 4 | 2025 | 572 | 0.260 |
Why?
| | Chemokines, CXC | 1 | 2007 | 68 | 0.250 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 130 | 0.250 |
Why?
| | Adaptive Immunity | 2 | 2019 | 167 | 0.250 |
Why?
| | Immunity, Innate | 7 | 2025 | 835 | 0.240 |
Why?
| | Cells, Cultured | 6 | 2019 | 4148 | 0.240 |
Why?
| | Flow Cytometry | 4 | 2022 | 1162 | 0.240 |
Why?
| | Middle Aged | 13 | 2026 | 36215 | 0.240 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 140 | 0.240 |
Why?
| | Tacrolimus | 3 | 2025 | 196 | 0.240 |
Why?
| | Chemokines | 1 | 2007 | 217 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1716 | 0.230 |
Why?
| | Phosphatidylethanolamines | 1 | 2026 | 76 | 0.230 |
Why?
| | Immune System Diseases | 1 | 2006 | 37 | 0.230 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 218 | 0.230 |
Why?
| | NF-kappa B | 3 | 2016 | 666 | 0.230 |
Why?
| | Protein Binding | 6 | 2019 | 2238 | 0.230 |
Why?
| | Organ Specificity | 3 | 2020 | 309 | 0.220 |
Why?
| | Rats | 9 | 2024 | 5584 | 0.220 |
Why?
| | Pilot Projects | 3 | 2021 | 1891 | 0.220 |
Why?
| | Biopsy | 3 | 2019 | 1082 | 0.220 |
Why?
| | Proteinuria | 4 | 2026 | 104 | 0.220 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 26 | 0.220 |
Why?
| | Caspases | 1 | 2006 | 233 | 0.220 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 29 | 0.210 |
Why?
| | Fetal Death | 1 | 2005 | 57 | 0.210 |
Why?
| | Child | 12 | 2025 | 22707 | 0.210 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 21 | 0.210 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 450 | 0.200 |
Why?
| | Platelet Activation | 1 | 2024 | 99 | 0.200 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 41 | 0.200 |
Why?
| | Macular Degeneration | 3 | 2012 | 191 | 0.200 |
Why?
| | Membrane Glycoproteins | 2 | 2026 | 499 | 0.200 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 11 | 0.200 |
Why?
| | Transplant Recipients | 1 | 2025 | 181 | 0.190 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 36 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 115 | 0.180 |
Why?
| | Ischemia | 3 | 2015 | 422 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2021 | 3623 | 0.180 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 229 | 0.180 |
Why?
| | CD59 Antigens | 3 | 2011 | 20 | 0.170 |
Why?
| | Apoptosis | 2 | 2011 | 2440 | 0.170 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 78 | 0.170 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 32 | 0.170 |
Why?
| | Proteomics | 4 | 2018 | 1188 | 0.170 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 560 | 0.170 |
Why?
| | Myoglobin | 1 | 2021 | 12 | 0.170 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 13 | 0.170 |
Why?
| | Immune System | 1 | 2022 | 180 | 0.170 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 32 | 0.170 |
Why?
| | Glutamic Acid | 1 | 2023 | 255 | 0.160 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 56 | 0.160 |
Why?
| | Frozen Sections | 1 | 2021 | 24 | 0.160 |
Why?
| | Paraffin Embedding | 1 | 2021 | 33 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 471 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2024 | 1957 | 0.160 |
Why?
| | Albuminuria | 2 | 2015 | 189 | 0.160 |
Why?
| | Formaldehyde | 1 | 2021 | 65 | 0.160 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 21 | 0.160 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 24 | 0.160 |
Why?
| | Staining and Labeling | 1 | 2021 | 153 | 0.160 |
Why?
| | Up-Regulation | 3 | 2019 | 847 | 0.160 |
Why?
| | Dendritic Cells | 2 | 2022 | 499 | 0.150 |
Why?
| | Lung | 6 | 2024 | 4106 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 171 | 0.150 |
Why?
| | Aged | 8 | 2021 | 26153 | 0.150 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 14 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 552 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.150 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 170 | 0.150 |
Why?
| | Urinalysis | 1 | 2019 | 83 | 0.140 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1996 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2021 | 11772 | 0.140 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 136 | 0.140 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.140 |
Why?
| | North America | 1 | 2019 | 302 | 0.140 |
Why?
| | Complement C5 | 3 | 2020 | 33 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 900 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 977 | 0.140 |
Why?
| | Sepsis | 2 | 2016 | 664 | 0.140 |
Why?
| | Adolescent | 8 | 2025 | 22530 | 0.140 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 14 | 0.140 |
Why?
| | Granulocytes | 2 | 2016 | 81 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2930 | 0.130 |
Why?
| | Organelles | 1 | 1998 | 55 | 0.130 |
Why?
| | HLA Antigens | 1 | 2019 | 240 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2020 | 209 | 0.130 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 22 | 0.130 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.130 |
Why?
| | Gene Expression | 6 | 2017 | 1476 | 0.130 |
Why?
| | Cyclophilins | 1 | 2017 | 40 | 0.130 |
Why?
| | Erythrocytes | 2 | 2020 | 748 | 0.130 |
Why?
| | Brain Injuries | 3 | 2007 | 507 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 13 | 0.130 |
Why?
| | Brachial Artery | 1 | 2018 | 208 | 0.120 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.120 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 858 | 0.120 |
Why?
| | Liraglutide | 1 | 2016 | 32 | 0.120 |
Why?
| | Interferon-beta | 2 | 2007 | 92 | 0.120 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 136 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2022 | 2046 | 0.120 |
Why?
| | Cell Aggregation | 1 | 2016 | 19 | 0.120 |
Why?
| | Bleomycin | 1 | 2018 | 255 | 0.120 |
Why?
| | Sulfonylurea Compounds | 1 | 2016 | 51 | 0.120 |
Why?
| | Insulin, Long-Acting | 1 | 2016 | 65 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 81 | 0.120 |
Why?
| | Blood Pressure | 1 | 2003 | 1779 | 0.120 |
Why?
| | Phenols | 1 | 2017 | 106 | 0.120 |
Why?
| | Ear, Middle | 3 | 2012 | 84 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 686 | 0.120 |
Why?
| | Collagen Type VII | 3 | 2018 | 27 | 0.120 |
Why?
| | Interferon-alpha | 2 | 2007 | 193 | 0.120 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 283 | 0.120 |
Why?
| | Macrophages | 3 | 2013 | 1507 | 0.110 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 318 | 0.110 |
Why?
| | Carboxypeptidases | 1 | 2015 | 12 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1061 | 0.110 |
Why?
| | Inflammation Mediators | 3 | 2019 | 506 | 0.110 |
Why?
| | Immunoprecipitation | 1 | 2016 | 148 | 0.110 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5423 | 0.110 |
Why?
| | Mitochondria | 2 | 2024 | 992 | 0.110 |
Why?
| | Mucin-5B | 1 | 2018 | 234 | 0.110 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 29 | 0.110 |
Why?
| | Prospective Studies | 4 | 2023 | 8057 | 0.110 |
Why?
| | Analysis of Variance | 2 | 2010 | 1300 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.110 |
Why?
| | Vaccinia virus | 1 | 2015 | 35 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 440 | 0.110 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 5 | 0.110 |
Why?
| | Vasodilation | 1 | 2018 | 521 | 0.110 |
Why?
| | Ultrasonography | 1 | 2018 | 785 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1368 | 0.100 |
Why?
| | Edema | 1 | 2015 | 125 | 0.100 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.100 |
Why?
| | Hypertension | 1 | 2003 | 1273 | 0.100 |
Why?
| | Eustachian Tube | 1 | 2014 | 9 | 0.100 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 118 | 0.100 |
Why?
| | Fibroblasts | 1 | 2020 | 1025 | 0.100 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 210 | 0.100 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.100 |
Why?
| | Models, Immunological | 2 | 2012 | 99 | 0.100 |
Why?
| | Immunoglobulins | 2 | 2020 | 162 | 0.100 |
Why?
| | Neutrophils | 2 | 2013 | 1124 | 0.100 |
Why?
| | Mast Cells | 1 | 2015 | 147 | 0.100 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.100 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 71 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 337 | 0.100 |
Why?
| | Cricetulus | 2 | 2010 | 118 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 120 | 0.100 |
Why?
| | CHO Cells | 2 | 2010 | 169 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 418 | 0.100 |
Why?
| | Cricetinae | 2 | 2010 | 305 | 0.090 |
Why?
| | Serum | 1 | 2013 | 58 | 0.090 |
Why?
| | Genotype | 1 | 2018 | 1852 | 0.090 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 87 | 0.090 |
Why?
| | Genetic Variation | 1 | 2018 | 972 | 0.090 |
Why?
| | Recurrence | 1 | 2016 | 1138 | 0.090 |
Why?
| | Metformin | 1 | 2016 | 329 | 0.090 |
Why?
| | Acute Disease | 3 | 2014 | 1036 | 0.090 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 132 | 0.090 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1132 | 0.090 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.090 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 171 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2016 | 730 | 0.090 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 69 | 0.090 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 373 | 0.090 |
Why?
| | Amino Acids | 1 | 2016 | 519 | 0.090 |
Why?
| | Rhadinovirus | 1 | 2012 | 20 | 0.090 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 384 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 280 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 305 | 0.090 |
Why?
| | Skin | 2 | 2015 | 753 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 666 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 51 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 210 | 0.090 |
Why?
| | Pregnancy | 4 | 2018 | 7202 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 104 | 0.080 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 546 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2011 | 38 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1140 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.080 |
Why?
| | Down-Regulation | 4 | 2020 | 618 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 148 | 0.080 |
Why?
| | Tissue Distribution | 3 | 2019 | 335 | 0.080 |
Why?
| | Plasma Exchange | 1 | 2010 | 18 | 0.080 |
Why?
| | Risk Factors | 1 | 2025 | 10885 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.080 |
Why?
| | Blister | 2 | 2008 | 39 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 692 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 925 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1508 | 0.080 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 38 | 0.080 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 14 | 0.080 |
Why?
| | Opsonin Proteins | 1 | 2010 | 19 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2013 | 401 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 89 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2015 | 1111 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 84 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 53 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 83 | 0.070 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 361 | 0.070 |
Why?
| | Antibody Formation | 1 | 2010 | 288 | 0.070 |
Why?
| | Osteoarthritis | 1 | 2011 | 200 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 408 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2010 | 247 | 0.070 |
Why?
| | Image Enhancement | 1 | 2010 | 200 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7123 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 386 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2022 | 2803 | 0.070 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1244 | 0.070 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 13 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2769 | 0.070 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 61 | 0.070 |
Why?
| | Cattle | 2 | 2026 | 946 | 0.070 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 35 | 0.060 |
Why?
| | Bacteremia | 1 | 2010 | 222 | 0.060 |
Why?
| | Hemolysis | 2 | 2020 | 242 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1044 | 0.060 |
Why?
| | Binding Sites | 3 | 2016 | 1310 | 0.060 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 41 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2378 | 0.060 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 76 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1767 | 0.060 |
Why?
| | Neurons | 2 | 2006 | 1649 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1399 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 2017 | 538 | 0.060 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 14219 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 58 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 196 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2006 | 90 | 0.060 |
Why?
| | Leukocytes | 1 | 2008 | 296 | 0.060 |
Why?
| | Integrin beta1 | 1 | 2026 | 33 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 155 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 892 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 163 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2188 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 7 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 779 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 466 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2524 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 32 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 592 | 0.060 |
Why?
| | Probability | 1 | 2006 | 307 | 0.050 |
Why?
| | Random Allocation | 1 | 2006 | 365 | 0.050 |
Why?
| | Child, Preschool | 3 | 2025 | 11853 | 0.050 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 154 | 0.050 |
Why?
| | Aristolochic Acids | 1 | 2024 | 1 | 0.050 |
Why?
| | Placental Insufficiency | 1 | 2006 | 126 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4075 | 0.050 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2005 | 61 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 177 | 0.050 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 147 | 0.050 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.050 |
Why?
| | Lung Transplantation | 1 | 2007 | 332 | 0.050 |
Why?
| | Schistosomiasis | 1 | 2024 | 50 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2664 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3342 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 457 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1164 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 193 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 395 | 0.050 |
Why?
| | Myocardium | 1 | 2009 | 934 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 372 | 0.050 |
Why?
| | Drinking Behavior | 1 | 2003 | 15 | 0.050 |
Why?
| | Compulsive Behavior | 1 | 2003 | 6 | 0.050 |
Why?
| | Brain | 2 | 2006 | 2947 | 0.050 |
Why?
| | Lung Injury | 1 | 2006 | 244 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 1 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 2 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 25 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 37 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 55 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 53 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 376 | 0.050 |
Why?
| | Folic Acid | 1 | 2024 | 198 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2158 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 223 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 224 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 67 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 728 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 349 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 198 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 161 | 0.050 |
Why?
| | Energy Metabolism | 2 | 2019 | 935 | 0.040 |
Why?
| | Neutralization Tests | 2 | 2015 | 76 | 0.040 |
Why?
| | Drug Combinations | 2 | 2016 | 396 | 0.040 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 36 | 0.040 |
Why?
| | HLA-D Antigens | 1 | 2022 | 30 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2588 | 0.040 |
Why?
| | Metabolome | 1 | 2025 | 388 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 254 | 0.040 |
Why?
| | Ubiquitination | 1 | 2022 | 118 | 0.040 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 77 | 0.040 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2022 | 207 | 0.040 |
Why?
| | Cholecalciferol | 1 | 2021 | 61 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2129 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 37 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 593 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 138 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 192 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 364 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 381 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 104 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 103 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 611 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 959 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 23 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 49 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 84 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 199 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 295 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 638 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 161 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 174 | 0.030 |
Why?
| | Brefeldin A | 1 | 1998 | 8 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2020 | 389 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3542 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 333 | 0.030 |
Why?
| | Cyclopentanes | 1 | 1998 | 17 | 0.030 |
Why?
| | Immunity, Active | 1 | 1998 | 8 | 0.030 |
Why?
| | Cell Compartmentation | 1 | 1998 | 52 | 0.030 |
Why?
| | A549 Cells | 1 | 2018 | 75 | 0.030 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 27 | 0.030 |
Why?
| | Parasitemia | 1 | 1998 | 15 | 0.030 |
Why?
| | Aotidae | 1 | 1998 | 10 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 396 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 48 | 0.030 |
Why?
| | Macrolides | 1 | 1998 | 67 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 68 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 665 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 403 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 387 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 135 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 99 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 171 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1217 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 203 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 64 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 69 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 106 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 21 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 437 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 212 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 312 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 127 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 147 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 35 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 924 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 70 | 0.030 |
Why?
| | Infant | 1 | 2009 | 10077 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 26 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 83 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 247 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 207 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 239 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 207 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 804 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 268 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 934 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 674 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 37 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 5 | 0.020 |
Why?
| | HeLa Cells | 1 | 2015 | 632 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2883 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1246 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 302 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2105 | 0.020 |
Why?
| | Pyridones | 1 | 2015 | 209 | 0.020 |
Why?
| | Drug Synergism | 1 | 2014 | 354 | 0.020 |
Why?
| | International Cooperation | 1 | 2013 | 197 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2187 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 119 | 0.020 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 159 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 391 | 0.020 |
Why?
| | Coinfection | 1 | 2014 | 143 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 84 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 81 | 0.020 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1048 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 25 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 67 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 177 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2016 | 479 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2062 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 194 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 381 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 450 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 172 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 372 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 174 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 674 | 0.020 |
Why?
| | Joints | 1 | 2011 | 106 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 340 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 288 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 462 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 105 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 310 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 197 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 173 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 627 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 402 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 302 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1374 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 232 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 486 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 532 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 427 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 265 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1048 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1041 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2121 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 855 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 55 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 29 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 169 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 82 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 20 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 894 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1923 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 142 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 749 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2170 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 381 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 20 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 61 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 62 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 51 | 0.010 |
Why?
| | Vaccination | 1 | 2015 | 1426 | 0.010 |
Why?
| | Protein Transport | 1 | 2008 | 442 | 0.010 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 49 | 0.010 |
Why?
| | Blood Glucose | 1 | 2016 | 2341 | 0.010 |
Why?
| | fas Receptor | 1 | 2006 | 91 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 74 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 115 | 0.010 |
Why?
| | Trachea | 1 | 2007 | 258 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 234 | 0.010 |
Why?
| | Synovial Membrane | 1 | 2006 | 123 | 0.010 |
Why?
| | Models, Molecular | 1 | 2010 | 1598 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5905 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 309 | 0.010 |
Why?
| | Cell Death | 1 | 2006 | 382 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3413 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3155 | 0.010 |
Why?
| | Swine | 1 | 2006 | 825 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 539 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 20 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 31 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 324 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 998 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 168 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1100 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 519 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 776 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2597 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1764 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 101 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2028 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1210 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 1797 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 786 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2906 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 27 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 179 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 403 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|